Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 460

Sort by

Sort Order Select

Journal Articles

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Blood (2024) 143 (20): 2059–2072.

https://doi.org/10.1182/blood.2023022832

Published: 2024

Includes: Supplemental data

Journal Articles

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Blood (2023) 142 (19): 1647–1657.

https://doi.org/10.1182/blood.2023020649

Published: 2023

Includes: Supplemental data

Journal Articles

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

Blood (2023) 142 (Supplement 1): 1545.

https://doi.org/10.1182/blood-2023-189966

Published: 2023

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Blood (2023) 142 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2023-189711

Published: 2023

Journal Articles

Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens

Naszrin Arani, Emmanuel Almanza, Alex Bataller, Courtney D. DiNardo, Farhad Ravandi, Naval Daver, Naveen Pemmaraju, Musa Yilmaz, Abhishek Maiti, Patrick K Reville, Sanam Loghavi, Hussein A Abbas, Guillermo Garcia-Manero, Nicholas J. Short, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4236.

https://doi.org/10.1182/blood-2023-191181

Published: 2023

Journal Articles

Unmet Medical Needs Amongst Older Patients Aged ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy: Experience from a Predominately United States Community Setting

Tapan M. Kadia, Alex Bataller, Esprit Ma, Achal Patel, Rongrong Wang, Archibong Yellow-Duke, Melissa Montez, Cat N. Bui, Farhad Ravandi

Blood (2023) 142 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2023-178004

Published: 2023

Journal Articles

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Lucia Masarova, Meixian Huang, Sharon Bledsoe, Naveen Pemmaraju, Tapan M. Kadia, Prithviraj Bose, Jo Ishizawa, Guillermo Montalban-Bravo, Mi-Ae Lyu, Ke Zeng, Tara Sadeghi, Ekatherine Asatiani, Simrit Parmar, Christopher R. Flowers, Hagop M. Kantarjian

Blood (2023) 142 (Supplement 1): 1813.

https://doi.org/10.1182/blood-2023-188051

Published: 2023

Journal Articles

Cladribine with Low Dose Cytarabine and Venetoclax Alternated with Azacytidine and Venetoclax for Acute Myeloid Leukemia: Prognostic Analysis of a Phase 2 Clinical Trial

Alex Bataller, Alexandre Bazinet, Gautam Borthakur, Nicholas J. Short, Elias Jabbour, Koichi Takahashi, Naval Daver, Ghayas C. Issa, Courtney D. DiNardo, Naveen Pemmaraju, Nitin Jain, Guillermo Montalban-Bravo, William G. Wierda, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4256.

https://doi.org/10.1182/blood-2023-182250

Published: 2023

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1857.

https://doi.org/10.1182/blood-2023-189557

Published: 2023

Journal Articles

Protective Role of Oxaliplatin Among Platinum-Based Therapies in the Development of Therapy-Related Myeloid Neoplasms

Jeremy S Connors, Linda Zhang, Koji Sasaki, Courtney D. DiNardo, Nicholas J. Short, Naval Daver, Gautam Borthakur, Tapan M. Kadia, Hagop Kantarjian, Elias Jabbour, Margaret A Goodell, Guillermo Garcia-Manero, Koichi Takahashi

Blood (2023) 142 (Supplement 1): 4220.

https://doi.org/10.1182/blood-2023-190672

Published: 2023

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood (2023) 142 (Supplement 1): 3267.

https://doi.org/10.1182/blood-2023-188084

Published: 2023

Journal Articles

Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Guillermo Montalban-Bravo, Elias Jabbour, Kelly S. Chien, Gautam Borthakur, Zeev Estrov, Tapan M. Kadia, Farhad Ravandi, Naveen Pemmaraju, Graciela Nogueras-Gonzalez, Heather Schneider, Rosmy John, Meghan Anne Meyer, Hagop M. Kantarjian, Guillermo Garcia-Manero, Xiao Qin DONG

Blood (2023) 142 (Supplement 1): 1873.

https://doi.org/10.1182/blood-2023-178110

Published: 2023

Journal Articles

Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria

Samuel Urrutia, Kelly S. Chien, Ziyi Li, Gautam Borthakur, Yesid Alvarado Valero, Tapan M. Kadia, Steven M. Kornblau, Naval Daver, Farhad Ravandi, Prithviraj Bose, Musa Yilmaz, Maro Ohanian, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1877.

https://doi.org/10.1182/blood-2023-184690

Published: 2023

Journal Articles

A Phase 2 Study of Canakinumab in Patients with Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Juan Jose Rodriguez Sevilla, Vera Adema, Kelly S. Chien, Irene Ganan-Gomez, Guillermo Montalban-Bravo, Samuel Urrutia, Joby Joseph, Hui Yang, Gautam Borthakur, Nicholas J. Short, Ghayas C. Issa, Tapan M. Kadia, Koichi Takahashi, Danielle E. Hammond, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1866.

https://doi.org/10.1182/blood-2023-185259

Published: 2023

Journal Articles

Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features

Hussain Alcassab, Koji Sasaki, Danielle E. Hammond, Alex Bataller, David B Beck, Tapan M. Kadia, Guillermo Montalban-Bravo, Kelly S. Chien, L. Jeffrey Medeiros, Hagop Kantarjian, Awdesh Kalia, Manjunath Nimmakayalu, Carlos E. Bueso-Ramos, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna

Blood (2023) 142 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2023-190464

Published: 2023

Journal Articles

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML

Blood (2023) 142 (Supplement 1): 1575.

https://doi.org/10.1182/blood-2023-185135

Published: 2023

Journal Articles

Poor Outcome of Patients with Acute Myeloid Leukemia in First Relapse Underscores the Need for Effective Initial Treatment

Alex Bataller, Hagop M. Kantarjian, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Musa Yilmaz, Ghayas C. Issa, Yesid Alvarado Valero, Guillermo Montalban-Bravo, Abhishek Maiti, Hussein A Abbas, Elias Jabbour, William G. Wierda, Guillermo Garcia-Manero, Farhad Ravandi

Blood (2023) 142 (Supplement 1): 1480.

https://doi.org/10.1182/blood-2023-179245

Published: 2023

Journal Articles

TP53 Y220C Mutations in Patients with Myeloid Malignancies

Georgina Gener-Ricos, Jan Philipp Bewersdorf, Sanam Loghavi, Aaron D. Goldberg, Christopher Famulare, Ghayas C. Issa, Gautam Borthakur, Tapan M. Kadia, Bing Z. Carter, Keyur P. Patel, Michael Andreeff, Eytan M. Stein, Courtney D. DiNardo

Blood (2023) 142 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2023-189343

Published: 2023

Journal Articles

NPM1-Mutated Myeloid Neoplasms: Updated Outcomes with High-Intensive Chemotherapy Regardless of the Blast Percentage

Georgina Gener-Ricos, Alex Bataller, Emmanuel Almanza-Huante, Kelly S. Chien, Danielle E. Hammond, Koji Sasaki, Courtney D. DiNardo, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Ghayas C. Issa, Nicholas J. Short, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2023) 142 (Supplement 1): 957.

https://doi.org/10.1182/blood-2023-187676

Published: 2023

Journal Articles

Five-Year Follow up Results of Phase II Clinical Trial Evaluating Ruxolitinib (RUX) and Azacitidine (AZA) Combination Therapy in Patients (pts) with Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Sankalp Arora, Jayastu Senapati, Naveen Pemmaraju, Prithviraj Bose, Lucia Masarova, Guillermo Montalban-Bravo, Abhishek Maiti, Tapan M. Kadia, Elias Jabbour, Guillermo Garcia-Manero, Hagop M. Kantarjian, Naval Daver

Blood (2023) 142 (Supplement 1): 1861.

https://doi.org/10.1182/blood-2023-187035

Published: 2023

NARROW

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens

Unmet Medical Needs Amongst Older Patients Aged ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy: Experience from a Predominately United States Community Setting

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Cladribine with Low Dose Cytarabine and Venetoclax Alternated with Azacytidine and Venetoclax for Acute Myeloid Leukemia: Prognostic Analysis of a Phase 2 Clinical Trial

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Protective Role of Oxaliplatin Among Platinum-Based Therapies in the Development of Therapy-Related Myeloid Neoplasms

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria

A Phase 2 Study of Canakinumab in Patients with Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML

Poor Outcome of Patients with Acute Myeloid Leukemia in First Relapse Underscores the Need for Effective Initial Treatment

TP53 Y220C Mutations in Patients with Myeloid Malignancies

NPM1-Mutated Myeloid Neoplasms: Updated Outcomes with High-Intensive Chemotherapy Regardless of the Blast Percentage

Five-Year Follow up Results of Phase II Clinical Trial Evaluating Ruxolitinib (RUX) and Azacitidine (AZA) Combination Therapy in Patients (pts) with Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only